Prostate immune system plays a critical role in the regulation of prostate cancer
development regarding androgen-deprivation therapy (ADT) and/or immunotherapy …

Immunotherapy, by enhancing the endogenous anti-tumor immune responses, is showing
promising results for the treatment of numerous cancers refractory to conventional therapies …

Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading
cause of cancer-related death in American men. Androgen deprivation therapy (ADT) has …

Androgen deprivation therapy (ADT) is a cornerstone treatment for locally advanced or
metastatic prostate cancer (PCa). However, its potential effects on the tumor immune …

Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT)
reduces prostate cancer (PCa) growth in virtually all patients, but response may be …

Despite advanced efforts in early diagnosis, aggressive surgical treatment, and use of
targeted chemotherapies, the prognosis for many cancers is still dismal. This emphasizes …

Immune microenvironment of prostate cancer (PCa) is implicated in disease progression.
However, previous studies have not fully explored PCa immune microenvironment. This …

Simple Summary The mainstay of treatment for advanced prostate cancer (PCa) is androgen
deprivation therapy (ADT), and although patients initially respond, almost all will eventually …

Background Therapeutic vaccination against disseminated prostate cancer (PCa) is partially
effective in some PCa patients. We hypothesized that the efficacy of treatment will be …

The prostate tumor microenvironment (TME) is strongly immunosuppressive; it is largely
driven by alteration in cell phenotypes (ie tumor-associated macrophages and exhausted …